Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
May 3, 2018 4:00 PM EDTPresented Positive New Clinical Results from APOLLO Phase 3 Study of Patisiran, and Phase 1 and Phase 1/2 Open-Label Extension (OLE) Studies of Givosiran
Advanced Two Additional RNAi Therapeutics in Phase 3 Development: Inclisiran in ORION-9, -10, and -11 Studies, and Fitusiran in the ATLAS Program
Company Provides Positive New Development Updates on Phase 3 Programs for Givosiran and Lumasiran
Maintained Strong Balance Sheet with $1.6 Billion in Cash and Plans to End 2018 with Approximately $1.0 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
